Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al

Ann Rheum Dis. 2021 Oct;80(10):e165. doi: 10.1136/annrheumdis-2021-220957. Epub 2021 Aug 2.

Authors

Affiliations

¹ Rheumatology, University of Washington, Seattle, Washington, USA sarahhc@uw.edu.
² Rheumatology, University of Washington, Seattle, Washington, USA.
³ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
⁴ Department of Radiology, University of Washington, Seattle, Washington, USA.
⁵ Allergy and Infectious Disease, University of Washington, Seattle, Washington, USA.

PMID: 34340981
DOI: 10.1136/annrheumdis-2021-220957

No abstract available

Keywords: COVID-19; rituximab; vaccination.

Publication types

Letter
Comment

MeSH terms

COVID-19 Vaccines
COVID-19*
Humans
Immunity, Cellular
Rituximab
SARS-CoV-2*
Vaccination

Substances

COVID-19 Vaccines
Rituximab